Detalles de la búsqueda
1.
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
N Engl J Med
; 2024 Jun 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38828946
2.
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
Br J Cancer
; 130(10): 1679-1686, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38575731
3.
Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Oncology
; 102(4): 318-326, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-37778345
4.
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study.
Invest New Drugs
; 41(2): 306-316, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36892745
5.
Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations: a plain language summary.
Future Oncol
; 19(4): 291-297, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36794564
6.
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.
Future Oncol
; 19(19): 1319-1329, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37212796
7.
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Lancet Oncol
; 23(6): 781-792, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35576957
8.
Precision Management of Advanced Non-Small Cell Lung Cancer.
Annu Rev Med
; 71: 117-136, 2020 01 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-31986082
9.
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer.
Future Oncol
; 18(28): 3133-3141, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35950566
10.
PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer.
Future Oncol
; 18(14): 1793-1799, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35156837
11.
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 379(21): 2027-2039, 2018 11 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30280657
12.
Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
Future Oncol
; 17(32): 4237-4247, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34423676
13.
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Lancet Oncol
; 21(3): 373-386, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32027846
14.
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.
Br J Cancer
; 122(9): 1324-1332, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32161368
15.
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
Oncologist
; 25(8): 702-711, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32386255
16.
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
Invest New Drugs
; 38(1): 99-110, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30825104
17.
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
Int J Cancer
; 144(11): 2887-2896, 2019 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30485437
18.
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors.
Oncologist
; 24(12): e1417-e1425, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31127020
19.
Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.
J Nanobiotechnology
; 17(1): 89, 2019 Aug 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31426807
20.
Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
J Formos Med Assoc
; 118(1 Pt 2): 230-236, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29709339